+7(495)150-11-22 
+7(800)250-87-00 
+7(499)110-40-67 
PANKRATOV ANDREY ALEXANDROVICH
POSITION: Head of the Microsurgery Department at the P. Hertsen Moscow Oncology Research Institute – branch of the Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of Russian Federation
ACADEMIC DEGREE: Candidate of Biological Sciences
- Pankratov A.A., Head of Department, PhD in Biology
- Nemtsova E.R., Leading Researcher, Doctor of Biology
- Bezborodova O.A., Leading Researcher, Doctor of Biology
- Morozova N.B., Senior Researcher, PhD in Biology
- Plotnikova E.A., Senior Researcher, PhD in Biology
- Trunova G.V., Senior Researcher, PhD in Biology
- Plyutinskaya A.D., Senior Researcher, PhD in Biology
- Venediktova Y.B., Junior Researcher
- Vorantsova M.S., Junior Researcher
- Noev A.S., Junior Researcher
- Dolgacheva E.A., Senior Laboratory Researcher
- The activities of the Department of Experimental Pharmacology and Toxicology are aimed at conducting experimental (medical-biological) and preclinical studies of medicinal products (MP), immunobiological preparations (IBP), radiopharmaceuticals (RFP), biomedical cellular products (BCP), gene therapies (GT), as well as the development and implementation of methodological guidelines for the preclinical investigation of innovative medicinal products in accordance with national and international protocols:
- development of new approaches, methods, and recommendations for the diagnosis, treatment, and improvement of the quality of life of patients with malignant neoplasms;
- experimental (medical-biological) and preclinical study of the pharmacodynamics of drugs (DS), molecular-targeted agents (MTA), radiopharmaceuticals (RFP), biological response modifiers (BRM), and gene therapies (GT) in in vitro and in vivo test systems;
- development and characterization of relevant in vitro and in vivo test systems for the study of targeted drugs, MTAs, RFPs, BRMs, and GTs;
- study of the effects of drugs, RFPs, and GTs on metastasis processes;
- study of the radio- and chemosensitizing properties of drugs;
- development of indications and criteria for evaluating the effectiveness of drugs that act as modifiers of therapeutic efficacy in radiotherapy and chemotherapy;
- assessment of therapeutic pathomorphosis;
- study of the mechanism of action of antitumor drugs and gene therapies;
- preclinical study of the general toxic properties and specific types of toxicity of drugs, IBP, RFP, GP, and BMCP in accordance with national and international protocols
- study of the pharmacological safety of drugs, biologically active substances (BAS), radiopharmaceuticals (RFP), gene preparations (GP), and biomedical cell products (BMCP);
- study of the mechanisms of toxic effects of drugs, BAS, and GP;
- study of the pharmacokinetics and biodistribution of drugs, BAS, RFP, GP, and BMCP;
- quality control of drugs based on physicochemical and biological quality indicators;
- participation in the program for the care of animals and their rational use in biomedical research;
- development and implementation of methodological guidelines for preclinical study of innovative drugs and RFP in accordance with national and international protocols.
- – Experimental oncology (in vitro and in vivo)
- – Experimental pharmacology (in vitro and in vivo)
- – Experimental toxicology
- – Preparative and analytical biochemistry
- – Preparative and analytical immunochemistry
- – Biochemistry and morphology of the blood of experimental animals and humans
- – Histology of internal organs and tissues
- – Immunocytochemistry and immunohistochemistry
- – Cellular immunology- Cellular immunology using flow cytometry
- Cytostatic Therapy
Doxorubicin-NF (clinical trials are being initiated in Phase I) - Fluorescent Diagnosis and Photodynamic Therapy
Photosens (registered, RN000199/02 2013-09-18)
Alasens (registered, LP-001848 2018-12-12)
Alasens-gel (preclinical studies completed)
Hexasens (Phase I clinical trials conducted)
Holosens-lyo (preclinical studies completed)
Holosens-gel (preclinical studies completed)
Liposome Chlorin e (preclinical studies completed)
Natural Bacteriochlorin (λ=800 nm; preclinical studies completed)
Synthetic Bacteriochlorin (λ=747 nm; preclinical studies completed) - Binary catalytic therapy
Terafthal (Phase II clinical trials completed)
Oxycobalamin (Phase II clinical trials)
Efiter (clinical trials completed) - Hyperthermia
Nanosense (preclinical studies completed)
Targeted therapyImuteran (Phase I clinical trials completed)
Manselan (preclinical studies completed) - Radionuclide Targeted Therapy
Targeted molecular therapy with Auger electron emitters (preclinical studies are being conducted)
Radiopharmaceuticals with beta-emitting radioisotopes lutetium-177 and lead-212
Radiopharmaceuticals based on samarium-153 in a thermosensitive carrier for local tumor radiotherapy (preclinical studies completed) - Gene Antitumor Therapy
Yelenagen (Phase II clinical trials)
AntioncoRAN-M (preclinical studies completed; initiation of clinical trials within Phase I)
AntioncoRAN-F (preclinical studies)
GenTherPlus (experimental studies) - Anti-inflammatory and Antioxidant
Therapy Lantox (preclinical studies)
Laprot (registered, Drug No. 002374, 2015-05-20)
Lactoftal (Phase II clinical trials)
AdeLact (Phase I clinical trials) - Metabolic, supportive therapy
Deltaran (registered, LP-003849 2016-09-20)
Remaxol (registered, LSR-009341/09 2020-02-13)
Runichol (preclinical studies) - Immunomodulatory therapy
GMDP-A (preclinical studies completed)
HLDF6 peptide (preclinical studies completed)
Antiviral therapyAdeVac-Flu (Phase I clinical trials)Dinavir (preclinical studies)
Panavir (registered, R N000299/02 2018-11-19)
GamEvac Vaccine vector against Ebola fever (registered, LP-003389 2015-12-28)
GamEvac-Combi Combined vector vaccine against Ebola fever (registered, LP-003390 2018-05-14)
Antirabitel (Phase I clinical trials) - Therapy for rare diseases
AdeVask (Phase I clinical trials) - Diagnostic drugs
Lymphotropin (preclinical studies)
BioNAF (preclinical studies completed)
